Are aging biomarkers clinically relevant in oncogeriatrics?

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 3, 2013, Pages 257-265

  Falandry, Claire ^a,b   Gilson, Eric ^c,d   Rudolph, K Lenhard ^e  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^d UNIVERSITY HOSPITAL OF NICE   (France)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Aging; Biomarker; Cancer; Elderly; Immunosenescence; Inflammaging; Oncogeriatrics; Telomere

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ELONGATION FACTOR 1ALPHA; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE H2AX; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PROTEIN P16; PROTEIN P21; RAP1 PROTEIN; STATHMIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AGE; AGING; BLADDER CANCER; CANCER INCIDENCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL AGING; CYTOMEGALOVIRUS INFECTION; DNA DAMAGE; DYSKERATOSIS CONGENITA; FRAIL ELDERLY; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; KIDNEY CANCER; LYMPHOCYTOPENIA; METASTASIS; NEOPLASM; NONHUMAN; PHENOTYPE; PREMATURE AGING; PROSTATE CANCER; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; TELOMERE; TELOMERE SHORTENING; TESTIS CANCER; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; CELL AGING; DNA DAMAGE; GERIATRICS; HUMANS; NEOPLASMS; TELOMERE;

EID: 84873523782     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.08.004     Document Type: Review

References (101)

1. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
2. Sieburg H.B., Cho R.H., Dykstra B., Uchida N., Eaves C.J., Muller-Sieburg C.E. The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets. Blood 2006, 107:2311-2316. [Epub 2005 November 15].
3. Wang J., Sun Q., Morita Y., et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell 2012, 148:1001-1014.
4. Wang J., Geiger H., Rudolph K.L. Immunoaging induced by hematopoietic stem cell aging. Current Opinion in Immunology 2011, 23:532-536.
5. Song Z., Wang J., Guachalla L.M., et al. Alterations of the systemic environment are the primary cause of impaired b and t lymphopoiesis in telomere-dysfunctional mice. Blood 2010, 115:1481-1489.
6. Ju Z., Jiang H., Jaworski M., et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nature Medicine 2007, 13:742-747.
7. Franceschi C., Capri M., Monti D., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mechanisms of Ageing and Development 2007, 128:92-105. [Epub 2006 November 20].
8. Jylha M., Paavilainen P., Lehtimaki T., et al. Interleukin-1 receptor antagonist, interleukin-6, and c-reactive protein as predictors of mortality in nonagenarians: the vitality 90+ study. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2007, 62:1016-1021.
9. Giovannini S., Onder G., Liperoti R., et al. Interleukin-6, c-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals. Journal of the American Geriatrics Society 2011, 2011:1532-5415.
10. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Experimental Cell Research 1961, 25:585-621.
11. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16ink4a. Cell 1997, 88:593-602.
12. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198. [Epub 2003 November 5].
13. Gilson E., Geli V. How telomeres are replicated. Nature Reviews Molecular Cell Biology 2007, 8:825-838.
14. Sedelnikova O.A., Horikawa I., Zimonjic D.B., Popescu N.C., Bonner W.M., Barrett J.C. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nature Cell Biology 2004, 6:168-170.
15. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends in Cell Biology 2001, 11:S27-S31.
16. Prieur A., Peeper D.S. Cellular senescence in vivo: a barrier to tumorigenesis. Current Opinion in Cell Biology 2008, 20:150-155. [Epub 2008 March 18].
17. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nature Reviews Cancer 2010, 10:51-57.
18. DeGregori J Evolved tumor suppression: why are we so good at not getting cancer?. Cancer 2011, 71:3739-3744. [Epub 2011 May 24].
19. Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Review of Pathology 2010, 5:99-118.
20. Rudolph K.L., Chang S., Lee H.W., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999, 96:701-712.
21. Pereira S., Bourgeois P., Navarro C., et al. Hgps and related premature aging disorders: from genomic identification to the first therapeutic approaches. Mechanisms of Ageing and Development 2008, 129:449-459.
22. Blasco M.A. Immunosenescence phenotypes in the telomerase knockout mouse. Springer Seminars in Immunopathology 2002, 24:75-85.
23. Vulliamy T.J., Marrone A., Knight S.W., Walne A., Mason P.J., Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006, 107:2680-2685.
24. Alter B.P., Baerlocher G.M., Savage S.A., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447. [Epub 2007 April 27].
25. Janzen V., Forkert R., Fleming H.E., et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16ink4a. Nature 2006, 443:421-426.
26. Sudo K., Ema H., Morita Y., Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. Journal of Experimental Medicine 2000, 192:1273-1280.
27. Dykstra B., Kent D., Bowie M., et al. Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell 2007, 1:218-229.
28. Challen G.A., Boles N.C., Chambers S.M., Goodell M.A. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell 2010, 6:265-278.
29. Cho R.H., Sieburg H.B., Muller-Sieburg C.E. A new mechanism for the aging of hematopoietic stem cells: aging changes the clonal composition of the stem cell compartment but not individual stem cells. Blood 2008, 111:5553-5561.
30. Roeder I., Horn K., Sieburg H.B., Cho R., Muller-Sieburg C., Loeffler M. Characterization and quantification of clonal heterogeneity among hematopoietic stem cells: a model-based approach. Blood 2008, 112:4874-4883.
31. Rossi D.J., Jamieson C.H., Weissman I.L. Stems cells and the pathways to aging and cancer. Cell 2008, 132:681-696.
32. Grubeck-Loebenstein B., Wick G. The aging of the immune system. Advances in Immunology 2002, 80:243-284.
33. Weng N.P. Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 2006, 24:495-499.
34. Jefferson T., Rivetti D., Rivetti A., Rudin M., Di Pietrantonj C., Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005, 366:1165-1174.
35. Targonski P.V., Jacobson R.M., Poland G.A. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007, 25:3066-3069. [Epub 2007 January 16].
36. Larbi A., Fulop T., Pawelec G. Immune receptor signaling, aging and autoimmunity. Advances in Experimental Medicine and Biology 2008, 640:312-324.
37. Weyand C.M., Goronzy J.J. Giant-cell arteritis and polymyalgia rheumatica. Annals of Internal Medicine 2003, 139:505-515.
38. Weyand C.M., Goronzy J.J. Medium- and large-vessel vasculitis. New England Journal of Medicine 2003, 349:160-169.
39. Shurin M.R., Shurin G.V., Chatta G.S. Aging and the dendritic cell system: implications for cancer. Critical Reviews in Oncology/Hematology 2007, 64:90-105. [Epub 2007 April 18].
40. Aapro M.S., Cameron D.A., Pettengell R., et al. Eortc guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 2006, 42:2433-2453.
41. Aapro M.S., Bohlius J., Cameron D.A., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 2011, 47:8-32.
42. Smith T.J., Khatcheressian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 24:3187-3205.
43. Greil R., Psenak O., Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Annals of Oncology 2008, 19:ii116-ii118.
44. Dees E.C., O'Reilly S., Goodman S.N., et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Investigation 2000, 18:521-529.
45. Chang B.D., Swift M.E., Shen M., Fang J., Broude E.V., Roninson I.B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:389-394. [Epub 2001 December 18].
46. Zhang H., Pan K.H., Cohen S.N. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:3251-3256. [Epub 2003 March 7].
47. Parrinello S., Coppe J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. Journal of Cell Science 2005, 118:485-496. [Epub 2005 January 18].
48. Bavik C., Coleman I., Dean J.P., Knudsen B., Plymate S., Nelson P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Research 2006, 66:794-802.
49. Coppe J.P., Patil C.K., Rodier F., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic ras and the p53 tumor suppressor. PLoS Biology 2008, 6:2853-2868.
50. Kuilman T., Peeper D.S. Senescence-messaging secretome: Sms-ing cellular stress. Nature Reviews Cancer 2009, 9:81-94. [Epub 2009 January 9].
51. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:12072-12077. [Epub 2001 October 2].
52. Liu D., Hornsby P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Research 2007, 67:3117-3126.
53. Xue W., Zender L., Miething C., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660. [Epub 2007 January 24].
54. Puzianowska-Kuznicka M., Kuznicki J. Genetic alterations in accelerated ageing syndromes. Do they play a role in natural ageing?. International Journal of Biochemistry and Cell Biology 2005, 37:947-960. [Epub 2004 December 15].
55. Meydani M., Lipman R.D., Han S.N., et al. The effect of long-term dietary supplementation with antioxidants. Annals of the New York Academy of Sciences 1998, 854:352-360.
56. Holst C.R., Nuovo G.J., Esteller M., et al. Methylation of p16(ink4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Research 2003, 63:1596-1601.
57. Lee S.J., Lindquist K., Segal M.R., Covinsky K.E. Development and validation of a prognostic index for 4-year mortality in older adults. Journal of the American Medical Association 2006, 295:801-808.
58. Prasad P.K., Signorello L.B., Friedman D.L., Boice J.D., Pukkala E. Long-term non-cancer mortality in pediatric and young adult cancer survivors in Finland. Pediatric Blood & Cancer 2012, 58:421-427.
59. Vaziri H., Benchimol S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Experimental Gerontology 1996, 31:295-301.
60. Rossi D.J., Seita J., Czechowicz A., Bhattacharya D., Bryder D., Weissman I.L. Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. Cell Cycle 2007, 6:2371-2376. [Epub 2007 July 18].
61. Rube C.E., Fricke A., Widmann T.A., et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS ONE 2011, 6:e17487.
62. Greider C.W., Blackburn E.H. The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987, 51:887-898.
63. Counter C.M. The roles of telomeres and telomerase in cell life span. Mutation Research 1996, 366:45-63.
64. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 2003, 361:393-395.
65. Heidinger B.J., Blount J.D., Boner W., Griffiths K., Metcalfe N.B., Monaghan P. Telomere length in early life predicts lifespan. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:1743-1748.
66. Fitzpatrick A.L., Kronmal R.A., Kimura M., et al. Leukocyte telomere length and mortality in the cardiovascular health study. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2011, 66:421-429.
67. Martin-Ruiz C.M., Gussekloo J., van Heemst D., von Zglinicki T., Westendorp R.G. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell 2005, 4:287-290.
68. Martin-Ruiz C., Jagger C., Kingston A., et al. Assessment of a large panel of candidate biomarkers of ageing in the newcastle 85+ study. Mechanisms of Ageing and Development 2011, 132:496-502. [Epub 2011 August 16].
69. Willeit P., Willeit J., Mayr A., et al. Telomere length and risk of incident cancer and cancer mortality. Journal of the American Medical Association 2010, 304:69-75.
70. Njajou O.T., Hsueh W.C., Blackburn E.H., et al. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2009, 64:860-864. [Epub 2009 May 12].
71. Hemann M.T., Strong M.A., Hao L.Y., Greider C.W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001, 107:67-77.
72. Jiang H., Schiffer E., Song Z., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:11299-11304.
73. Watabe-Rudolph M., Song Z., Lausser L., et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology 2012, 2012:8.
74. Giraud-Panis M.J., Pisano S., Poulet A., Le Du M.H., Gilson E. Structural identity of telomeric complexes. FEBS Letters 2010, 584:3785-3799.
75. Munoz P., Blanco R., Flores J.M., Blasco M.A. Xpf nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nature Genetics 2005, 37:1063-1071. [Epub 2005 September 4].
76. Augereau A., T'Kint de Roodenbeke C., Simonet T., et al. Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood 2011, 118:1316-1322.
77. Song Z., von Figura G., Liu Y., et al. Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 2010, 9:607-615. [Epub 2010 June 17].
78. Epel E.S., Blackburn E.H., Lin J., et al. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:17312-17315.
79. Penninx B.W., Guralnik J.M., Pahor M., et al. Chronically depressed mood and cancer risk in older persons. Journal of the National Cancer Institute 1998, 90:1888-1893.
80. Schneider M.G., Chiriboga D.A. Associations of stress and depressive symptoms with cancer in older Mexican Americans. Ethnicity and Disease 2005, 15:698-704.
81. Zhang X., Li J., Sejas D.P., Pang Q. The atm/p53/p21 pathway influences cell fate decision between apoptosis and senescence in reoxygenated hematopoietic progenitor cells. Journal of Biological Chemistry 2005, 280:19635-19640.
82. Kortlever R.M., Higgins P.J., Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biology 2006, 8:877-884. [Epub 2006 July 23].
83. Krishnamurthy J., Torrice C., Ramsey M.R., et al. Ink4a/arf expression is a biomarker of aging. Journal of Clinical Investigation 2004, 114:1299-1307.
84. Munro J., Barr N.I., Ireland H., Morrison V., Parkinson E.K. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Experimental Cell Research 2004, 295:525-538.
85. Liu Y., Johnson S.M., Fedoriw Y., et al. Expression of p16(ink4a) prevents cancer and promotes aging in lymphocytes. Blood 2011, 117:3257-3267. [Epub 2011 January 18].
86. Vandenberk B., Brouwers B., Hatse S., Wildiers H. P16 ink4a: a central player in cellular senescence and a promising aging biomarker in elderly cancer patients. Journal of Geriatric Oncology 2011, 2:259-269.
87. Blay J.Y., Chauvin F., Le Cesne A., et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Journal of Clinical Oncology 1996, 14:636-643.
88. Ray-Coquard I., Borg C., Bachelot T., et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. British Journal of Cancer 2003, 88:181-186.
89. Claude L., Perol D., Ray-Coquard I., et al. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiotherapy and Oncology 2005, 76:334-339.
90. Ray-Coquard I., Cropet C., Van Glabbeke M., et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Research 2009, 69:5383-5391. [Epub 2009 June 23].
91. Cretel E., Veen I., Pierres A., et al. Immune profile of elderly patients admitted in a geriatric short care unit. La Revue de Médecine Interne 2011, 32:275-282.
92. Wikby A., Mansson I.A., Johansson B., Strindhall J., Nilsson S.E. The immune risk profile is associated with age and gender: findings from three swedish population studies of individuals 20-100 years of age. Biogerontology 2008, 9:299-308.
93. Wikby A., Maxson P., Olsson J., Johansson B., Ferguson F.G. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the swedish longitudinal octo-immune study. Mechanisms of Ageing and Development 1998, 102:187-198.
94. Huppert F.A., Pinto E.M., Morgan K., Brayne C. Survival in a population sample is predicted by proportions of lymphocyte subsets. Mechanisms of Ageing and Development 2003, 124:449-451.
95. Gibson K.L., Wu Y.C., Barnett Y., et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009, 8:18-25. [Epub 2008 November 5].
96. Trzonkowski P., Mysliwska J., Szmit E., et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination - an impact of immunosenescence. Vaccine 2003, 21:3826-3836.
97. Chung H.Y., Cesari M., Anton S., et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Research Reviews 2009, 8:18-30. [Epub 2008 July 18].
98. Jylhava J., Hurme M. Gene variants as determinants of longevity: focus on the inflammatory factors. Pflugers Archiv 2009, 459:239-246.
99. Lencel P., Magne D. Inflammaging: the driving force in osteoporosis?. Medical Hypotheses 2011, 76:317-321.
100. Goto M. Inflammaging (inflammation+aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory?. BioScience Trends 2008, 2:218-230.
101. Saito K., Kihara K C-reactive protein as a biomarker for urological cancers. Nature Reviews Urology 2011, 8:659-666.